How liquid biopsies can change clinical practice in oncology

Autor: Siravegna, G., Mussolin, B., Venesio, T., Marsoni, S., Seoane, J., Dive, C., Papadopoulos, N., Kopetz, S., Corcoran, R.B., Siu, L.L., Bardelli, A. ^*

Publikováno v: In Annals of Oncology October 2019 30(10):1580-1590

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Autor: Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., Whaley, A., Pinnelli, M., Murciano-Goroff, Y. R., Vakiani, E., Valeri, N., Liao, W. L., Bhalkikar, A., Thyparambil, S., Zhao, H. Y., de Stanchina, E., Marsoni, S., Siena, S., Bertotti, A., Trusolino, Livio, Li, B. T., Rosen, N., Di Nicolantonio, F., Bardelli, A., Misale, S.

Most patients withKRASG12C–mutant non–small cell lung cancer (NSCLC) experience clinical benefit from selective KRASG12Cinhibition, whereas patients with colorectal cancer bearing the same mutation rarely respond. To investigate the cause of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2659::ee86f2e68ce50ca9246b0f59786dab2c
https://zenodo.org/record/7794793

Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows

Autor: Lampignano , R., Neumann, M., Weber, S., Kloten, V., Herdean, A., Voss, T., Groelz, D., Babayan, A., Tibbesma, M., Schlumpberger, M., Chemi, F., Rothwell, D., Wikman, H., Galizzi, J., Bergheim, I., Russnes, H., Mussolin, B., Bonin, S., Voigt, C., Musa, H., Pinzani, P., Lianidou, E., Brady, G., Speicher, M., Pantel, K., Betsou, F., Schuuring, E., Kubista, M., Ammerlaan, W., Sprenger-Haussels, M., Schlange, T., Heitzer, E., Lehrach, H., Yaspo, M.

Publikováno v: Clinical Chemistry : International Journal of Molecular Diagnostics and Laboratory Medicine
Clinical Chemistry
Clinical Chemistry, 66(1), 149-160. AMER ASSOC CLINICAL CHEMISTRY

BACKGROUNDIn cancer patients, circulating cell-free DNA (ccfDNA) can contain tumor-derived DNA (ctDNA), which enables noninvasive diagnosis, real-time monitoring, and treatment susceptibility testing. However, ctDNA fractions are highly variable, whi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49907e8af53f9610c711a42c26a883cb
https://hdl.handle.net/10453/145203

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.